Vaxcyte Corporate Presentation

VAX-24 Preclinical POC Study Supports Potential to Deliver Broader-Spectrum PCV Functional Antibody (OPA) Responses (Current Standard for Approval in Adults) о 1 × 105 ✰ Comparable or better immune responses for VAX-24 relative to Prevnar 13 and Pneumovax 23 across all common strains. ❖ Potential for approval in adults based on non-inferiority relative to standard of care (≥ 50% of OPA titers one month post- vaccination). 13 Serotypes in Prevnar & Pneumovax 11 Serotypes in Pneumovax OPA Titer 1 × 10 4 1 × 10 3 1x102. 1 × 10 1 1 × 10° T --- --חשון Note: +/-95% confidence interval. 23 T 3 4 5 6A. 6B 7F A6 ・セレ 0.11ug VAX-24 18C 19A 19F 23F 0.11ug Prevnar 13 2 8 N6 1.1ug Pneumovax 23 10A- 11A- 12F- 15B 17F- 20- 22F 33F

View entire presentation